These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 9371866

  • 1. Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer?
    Bombardieri E, Martinetti A, Miceli R, Mariani L, Castellani MR, Seregni E.
    Eur J Nucl Med; 1997 Nov; 24(11):1349-55. PubMed ID: 9371866
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer.
    Koizumi M, Matsumoto S, Takahashi S, Yamashita T, Ogata E.
    Clin Nucl Med; 1999 Jan; 24(1):15-20. PubMed ID: 9890487
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
    Zissimopoulos A, Stellos K, Matthaios D, Petrakis G, Parmenopoulou V, Babatsikou F, Matthaiou E, Theodosiadou E, Hountis P, Koutis C.
    J BUON; 2009 Jan; 14(3):463-72. PubMed ID: 19810140
    [Abstract] [Full Text] [Related]

  • 9. Expressiveness of Bone Markers in Breast Cancer with Bone Metastases.
    Zulauf N, Brüggmann D, Groneberg D, Oremek GM.
    Oncology; 2019 Jan; 97(4):236-244. PubMed ID: 31412345
    [Abstract] [Full Text] [Related]

  • 10. Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer.
    Ulrich U, Rhiem K, Schmolling J, Flaskamp C, Paffenholz I, Sälzer H, Bauknecht T, Schlebusch H.
    Arch Gynecol Obstet; 2001 Jan; 264(4):186-90. PubMed ID: 11205705
    [Abstract] [Full Text] [Related]

  • 11. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer.
    Kylmälä T, Tammela TL, Risteli L, Risteli J, Kontturi M, Elomaa I.
    Br J Cancer; 1995 May; 71(5):1061-4. PubMed ID: 7734300
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer.
    Kanakis I, Nikolaou M, Pectasides D, Kiamouris C, Karamanos NK.
    J Pharm Biomed Anal; 2004 Mar 01; 34(4):827-32. PubMed ID: 15019061
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of bone metabolic markers in breast cancer with bone metastasis.
    Wada N, Fujisaki M, Ishii S, Ikeda T, Kitajima M.
    Breast Cancer; 2001 Mar 01; 8(2):131-7. PubMed ID: 11342986
    [Abstract] [Full Text] [Related]

  • 19. [Serum concentration of pyridinoline cross-linked carboxy-terminal telopeptide of type-I collagen (ICTP) and carboxyterminal propeptide of human type I procollagen (PICP) in the diagnosis of bone metastases].
    Koizumi M, Yamada Y, Takiguchi T, Suzuki C, Akashi T, Nomura E, Yamashita T, Ogata E.
    Kaku Igaku; 1996 Jan 01; 33(1):77-84. PubMed ID: 8819718
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.